JPWO2020188288A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188288A5 JPWO2020188288A5 JP2022504738A JP2022504738A JPWO2020188288A5 JP WO2020188288 A5 JPWO2020188288 A5 JP WO2020188288A5 JP 2022504738 A JP2022504738 A JP 2022504738A JP 2022504738 A JP2022504738 A JP 2022504738A JP WO2020188288 A5 JPWO2020188288 A5 JP WO2020188288A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound
- pharmaceutical composition
- composition according
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 206010006002 Bone pain Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010072132 Fracture pain Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 201000011252 Phenylketonuria Diseases 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000012241 membrane hyperpolarization Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000001242 postsynaptic effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1903900.7A GB2582361A (en) | 2019-03-21 | 2019-03-21 | Adenosine receptor agonists |
| GB1903900.7 | 2019-03-21 | ||
| PCT/GB2020/050734 WO2020188288A1 (en) | 2019-03-21 | 2020-03-19 | Adenosine receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525706A JP2022525706A (ja) | 2022-05-18 |
| JPWO2020188288A5 true JPWO2020188288A5 (https=) | 2023-03-27 |
| JP2022525706A5 JP2022525706A5 (https=) | 2023-03-27 |
Family
ID=66381433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504738A Pending JP2022525706A (ja) | 2019-03-21 | 2020-03-19 | アデノシン受容体アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220152077A1 (https=) |
| EP (1) | EP3941482A1 (https=) |
| JP (1) | JP2022525706A (https=) |
| GB (1) | GB2582361A (https=) |
| WO (1) | WO2020188288A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113082020A (zh) * | 2021-04-08 | 2021-07-09 | 徐州医科大学 | 一种腺苷受体激动剂的增强剂及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK62692D0 (https=) * | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| GB9930085D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| GB9930079D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| GB9930075D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| CN103087133B (zh) * | 2004-05-26 | 2016-09-14 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
| WO2011011919A1 (zh) * | 2009-07-31 | 2011-02-03 | 新道生技股份有限公司 | 一种降血糖的组合物 |
| KR20130029049A (ko) * | 2010-03-26 | 2013-03-21 | 이노텍 파마슈티컬스 코포레이션 | 아데노신 화합물 및 이의 용도 |
| WO2017137528A1 (en) * | 2016-02-12 | 2017-08-17 | Charité - Universitätsmedizin Berlin | Adenosine a1 receptor agonist for use in treatment of status epilepticus |
-
2019
- 2019-03-21 GB GB1903900.7A patent/GB2582361A/en not_active Withdrawn
-
2020
- 2020-03-19 US US17/441,257 patent/US20220152077A1/en not_active Abandoned
- 2020-03-19 JP JP2022504738A patent/JP2022525706A/ja active Pending
- 2020-03-19 WO PCT/GB2020/050734 patent/WO2020188288A1/en not_active Ceased
- 2020-03-19 EP EP20715187.9A patent/EP3941482A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6089045B2 (ja) | 痛みの緩和または治療に使用するためのフェニルカルバメート化合物 | |
| JP2013139446A5 (https=) | ||
| RU2009124541A (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| CN1235579C (zh) | 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 | |
| JP2008520589A5 (https=) | ||
| JP2010529969A5 (https=) | ||
| JP2011525185A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2014518552A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JPWO2020188288A5 (https=) | ||
| JPWO2021026180A5 (https=) | ||
| JP2006511604A5 (https=) | ||
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| JP2019535715A5 (https=) | ||
| JP2004501079A5 (https=) | ||
| JP2021515749A5 (https=) | ||
| RU2010122972A (ru) | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида | |
| JP2011088919A (ja) | アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物 | |
| JP2004532854A5 (https=) | ||
| JP2019535787A5 (https=) | ||
| CN113272285B (zh) | 含噁二唑的化合物、和含有其的药物组合物 | |
| JP2021528479A5 (https=) | ||
| RU2019134182A (ru) | Новые способы лечения рассеянного склероза | |
| JP2015526447A5 (https=) |